Armata Pharmaceuticals Inc

ARMPAMEX · USD
2.66USD-0.33 (-11.04%)
115

Armata Pharmaceuticals Inc (ARMP) Covered Calls

Armata Pharmaceuticals Inc trades in the Biotechnology industry with an IV Rank of 12.30%, low versus the past year. ARMP's highest covered call setup is the $7.50 strike expiring Feb 19, 2027, sorted by theoretical annualized return. It's 93.80% out of the money with 98 days to expiration, a 95.09% return until expiration, and a 354.16% theoretical annualized return. Across the setups shown, annualized returns run from 61.38% to 354.16% at strikes between $5.00 and $7.50, with 98 to 189 days to expiration, as of Nov 13, 2026.

Read more

Running ARMP covered calls helps you generate income from Armata Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ARMP covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ARMP stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ARMP covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ARMP covered call is worth writing.

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

2027-02-19987.5093.800.050.40368.0095.09354.16-1.29+0.22280.35
2027-05-211895.0029.200.105.00123.0031.7861.38-2.58+0.8204.90

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank12.30% Low
  • Market cap (M$)111
  • 52 weeks high-80.04%
  • 52 weeks low9.12%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$17.50
    557.89% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-12
  • P/E—
  • Future P/E—
  • EPS (ttm)-7.08
  • EPS growth next 5 years38.99%

As of Nov 16, 2026